Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2-Reference-Cited by-同舟云学术

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2

Published:2021-04-19 Issue:5 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Painter Wendy P.¹^ORCID,Holman Wayne¹,Bush Jim A.²,Almazedi Firas²,Malik Hamzah²,Eraut Nicola C. J. E.²,Morin Merribeth J.¹,Szewczyk Laura J.¹,Painter George R.³

Affiliation:

1. Ridgeback Biotherapeutics LP, Miami, Florida, USA

2. Covance Clinical Research Unit Limited, Leeds, United Kingdom

3. Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA

Abstract

Molnupiravir (EIDD-2801/MK-4482), the prodrug of the active antiviral ribonucleoside analog β- d -N4-hydroxycytidine (NHC; EIDD-1931), has activity against a number of RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and seasonal and pandemic influenza viruses. Single and multiple doses of molnupiravir were evaluated in this first-in-human, phase 1, randomized, double-blind, placebo-controlled study in healthy volunteers, which included evaluation of the effect of food on pharmacokinetics.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02428-20

Reference11 articles.

1. World Health Organization. 2020. Novel coronavirus (2019-nCoV) situation report 1. World Health Organization, Geneva, Switzerland.

2. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

3. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia

4. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection

5. Small-Molecule Antiviral β- d - N 4 -Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A validated LC-MS/MS method for determination of Molnupiravir and Favipiravir in human plasma; Assessment of the remarkable potential synergistic effect against SARS-CoV-2 Infection: Application to a pharmacokinetic study in healthy Egyptian volunteers;Microchemical Journal;2024-02

2. Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors;European Journal of Medicinal Chemistry;2024-02

3. Identification and evaluation of antiviral activity of novel compounds targeting SARS-CoV-2 virus by enzymatic and antiviral assays, and computational analysis;Journal of Enzyme Inhibition and Medicinal Chemistry;2024-01-14

4. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance;Antimicrobial Agents and Chemotherapy;2024-01-10

5. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19;2024-01-08